TOI vs ONCO vs KO vs PEP vs CRVS

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). PepsiCo, Inc. (PEP) offers the better valuation at 24. 0x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PepsiCo, Inc.

(PEP) is the cheapest at 24. 0x versus The Coca-Cola Company at 27. 2x. On forward P/E, PepsiCo, Inc. is actually cheaper at 16. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus PepsiCo, Inc. 's 5. 11x.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +321. 6%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: KO returned +121. 1% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Corvus Pharmaceuticals, Inc. 's 2. 02β — meaning CRVS is approximately -1109% more volatile than KO relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 2% for PepsiCo, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to -13. 7% for PepsiCo, Inc.. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus PepsiCo, Inc. 's 5. 11x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, PepsiCo, Inc. (PEP) trades at 16. 7x forward P/E versus 25. 3x for The Coca-Cola Company — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 178. 0% to $33. 17.

In this comparison, PEP (3.

9% yield), KO (2. 5% yield) pay a dividend. TOI, ONCO, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, CRVS: -6. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TOI (Healthcare) and ONCO (Healthcare) and KO (Consumer Defensive) and PEP (Consumer Defensive) and CRVS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; ONCO is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; PEP is a mid-cap income-oriented stock; CRVS is a small-cap quality compounder stock. KO, PEP pay a dividend while TOI, ONCO, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.